Technologie s vlastnostmi ověřenými in vivo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Technology with the features verified in vivo
Authors

ŠMAJS David BOSÁK Juraj POMORSKÁ Katarína HRALA Matěj RŮŽIČKOVÁ Jana

Year of publication 2016
MU Faculty or unit

Faculty of Medicine

Citation
Description Yersinia sp. infections are the third most common bacterial infections of humans in the European Union. Yersinioses range from self-limited enteritis to life-threatening systemic infections. The most frequent manifestation is diarrhea, mainly affecting children. While antibiotic treatment is recommended for serious cases, rehydration and use of probiotics are often suggested for simple diarrheal cases. Colicin FY (54 kDa) is produced by a nonpathogenic isolate of Yersinia frederiksenii. Colicin FY recognizes a yersinia-specific outer membrane protein YiuR as a receptor molecule and thus its activity spectrum comprises strains of the genus Yersinia, especially strains of Y. enterocolitica. Under in vitro conditions, colicin FY inhibits all Y. enterocolitica strains, while all other tested enterobacterial strains are colicin FY resistant (Bosák et al., 2012, 2013). Thus, synthesis of colicin FY would represent an important feature of probiotics used for the treatment of yersiniosis. The technology (colicin FY) has been verified during in vivo conditions and antimicrobial activity of colicin was confirmed. However, the suitable system for delivery of active agens to infection has to be developed/optimized.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.